Neuropace

Neuropace Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Neuropace (NPCE) as of Nov 13, 2026 is 235.34. In the previous year, Cash Conversion Cycle (CCC) was 241.49 — a change of -2.55% (lower).

Cash Conversion Cycle

235.34

YoY

-2.55%

Last updated:

Cash Conversion Cycle (CCC) of Neuropace is 2025 235.34 . Cash Conversion Cycle (CCC) of Neuropace was 2024 241.49 . It decreases by -2.55% lower compared to the previous year.

The Neuropace Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2019
302.28 USD
Jan 1, 2020
274.73 USD
Jan 1, 2021
257.57 USD
Jan 1, 2022
272.10 USD
Jan 1, 2023
256.11 USD
Jan 1, 2024
241.49 USD
Jan 1, 2025
235.34 USD
The Neuropace Cash Conversion Cycle history
YEARCash Conversion CycleYoY
235.34-2.55%
241.49-5.71%
256.11-5.88%
272.10+5.64%
257.57-6.25%
274.73-9.11%
302.28—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuropace Stock analysis

What does Neuropace do? Neuropace Inc is a US-based company specializing in the development and manufacturing of medical devices. It is headquartered in Mountain View, California and has been operating since 2000. The company was founded as a spin-off from a study conducted by Dr. Martha Morrell at Stanford University, focusing on the treatment of epilepsy with implanted devices. Neuropace Inc's business model involves manufacturing and marketing medical devices for epilepsy treatment. These devices, known as neurostimulators, are implantable devices that send electrical impulses to the brain and can reduce epileptic seizures. The company has been involved in various areas of epilepsy treatment, including the development of devices for patients with pharmacoresistant focal epilepsies. These devices can be implanted in patients who do not respond to traditional treatments such as medications or surgeries. Neuropace Inc has also started focusing on the development of devices for epilepsy diagnosis. One of these devices is the ambulatory EEG monitor, which records brain activity and allows doctors to better detect epilepsy seizures. The company has launched a range of products to achieve its goal of enabling patients to have a better quality of life. The key product is the RNS neurostimulator, which is implanted in patients and continuously monitors brain activity using electrodes placed in the brain to monitor brain waves. When the neurostimulator detects unusual activity, it automatically sends impulses to the brain to prevent or reduce the occurrence of epileptic seizures. The benefit is that patients experience fewer seizures and can better organize and plan their daily lives. Neuropace Inc has a competitive position in the market with its products for treating pharmacoresistant focal epilepsies. The RNS neurostimulator is the only device approved by the US Food and Drug Administration FDA capable of reducing critical neurological outcomes in epilepsy. The company also has a strong presence in the field of epilepsy diagnosis, particularly with the ambulatory EEG monitor. Neuropace Inc has also formed strategic partnerships with other companies to bring its technologies to the market. The company has formed alliances with Medtronic, among others, for the marketing and distribution of the RNS neurostimulator. Through these partnerships, Neuropace Inc has expanded its reach in the market and strengthened its relationships with leading companies in the industry. In summary, Neuropace Inc is a company specializing in the development and manufacturing of medical devices for epilepsy treatment. The company has expanded its technologies to cover a broader range of epilepsy conditions and has achieved a high level of success with its products. With solid partnerships and a strong commitment to epilepsy treatment, Neuropace Inc is expected to continue leading the market for medical devices. Neuropace is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuropace stock

Cash Conversion Cycle (CCC) of Neuropace is 235.34 in 2025.

Cash Conversion Cycle (CCC) of Neuropace changed from 241.49 to 235.34, representing a -2.55% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Neuropace since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Neuropace with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Neuropace

All Key Metrics — Neuropace